FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
CSL Limited Stock AnalysisComprehensive stock analysis for CSL Limited (CSLLY) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCSLLY
CSLLY
CSL Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CSLLY
Home🔹Stocks🔹CSL Limited

CSL Limited

CSLLY•OTC

CSL Limited

CSLLY•OTC
Market cap
$100.29B
Sentiment

Your view on CSLLY

Mkt Cap
$100.29B
Sentiment
Your view
CSLLY
CSL Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CSLLY
Company Overview

Overview

What the company does, where it operates, and who runs it.

About CSL Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Gordon Naylor DipCompSc
Headquarters
45 Poplar Road, Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Gordon Naylor DipCompSc
Headquarters
45 Poplar Road, Melbourne, VIC, AU
Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for CSL Limited, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for CSL Limited. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for CSL Limited. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for CSL Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for CSL Limited. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

CSL Limited valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold CSL Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by CSL Limited executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming CSL Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming CSL Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for CSL Limited. Press releases and market coverage, newest first.

News

Latest Market News